ARDELYX, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
ARDELYX, INC. (ARDX) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$12.73 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-19
- ARDELYX, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$12.73M.
- ARDELYX, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$8.16M.
- ARDELYX, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$13.76M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$12.73M 10-K · filed 2026-02-19 |
| 2024-12-31 | -$8.16M 10-K · filed 2026-02-19 |
| 2023-12-31 | -$13.76M 10-K · filed 2026-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |